[Neurology]

Isabelle Chopard1, David Benninger1, Jean-François Demonet1

  • 1Service de neurologie, Département des neurosciences cliniques, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|January 17, 2018
PubMed

Ocrelizumab (Ocrevus), an anti-CD20 monoclonal antibody, has been approved for the treatment of multiple sclerosis. Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis. A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis. In the treatment of headaches, particularly migraines, non-pharmacological approaches have shown some interesting results. The criteria for Lewy body dementia have been revised. Generic use of lamotrigine does not result in recrudescence of epileptic seizures or adverse effects.